GlycoMimetics (GLYC) Q4 2024 earnings summary

Executive summary

• GlycoMimetics ceased all drug development after its lead candidate, uproleselan, failed to meet the primary endpoint in a Phase 3 AML trial; the company is now pursuing a merger with Crescent Biopharma, expected to close in Q2 2025.

• The company underwent a major restructuring in July 2024, reducing its workforce by 80% and shifting focus to strategic alternatives, including the Crescent merger and a $200M private placement.

• If the merger fails, GlycoMimetics may pursue dissolution and liquidation; current cash is expected to fund operations until the merger closes.

Financial highlights

• Net loss for 2024 was $37.9M, compared to $36.9M in 2023; no product revenue was recognized in 2024.

• Research and development expenses fell 29% year-over-year to $14.3M, reflecting the wind-down of operations.

• General and administrative expenses decreased 5% to $18.2M; restructuring and asset impairment charges totaled $7.5M.

• Cash and cash equivalents at year-end 2024 were $10.7M, down from $41.8M at the end of 2023.

• A $1.2M gain was recorded from the sale of rights to a prior drug candidate, rivipansel.

Outlook and guidance

• The merger with Crescent Biopharma is expected to close in Q2 2025, with Crescent's business becoming the primary focus.

• A $200M private placement is contingent on the merger's completion; if not consummated, GlycoMimetics may seek other strategic alternatives or liquidate.

• Management expresses substantial doubt about the company's ability to continue as a going concern without the merger and private placement.